# Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets

> **NCT06558045** · PHASE1 · COMPLETED · sponsor: **Dexa Medica Group** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rivaroxaban 20 mg film-coated tablet
- **DRUG:** Xarelto 20 mg film-coated tablet

## Key facts

- **NCT ID:** NCT06558045
- **Lead sponsor:** Dexa Medica Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-06
- **Primary completion:** 2023-07-18
- **Final completion:** 2023-10-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558045, "Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06558045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*